Published in Int J Cancer on February 01, 2011
The functional role of long non-coding RNA in human carcinomas. Mol Cancer (2011) 6.37
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol (2012) 3.40
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov (2013) 2.16
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One (2012) 1.56
LncRNA: a new player in 1α, 25(OH)(2) vitamin D(3) /VDR protection against skin cancer formation. Exp Dermatol (2014) 1.53
Long non-coding RNA in cancer. Int J Mol Sci (2013) 1.52
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget (2013) 1.48
Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer (2011) 1.47
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia (2012) 1.36
Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat Commun (2012) 1.27
Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol (2014) 1.23
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia (2011) 1.15
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio (2013) 1.15
The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia (2014) 1.09
Cancer epigenetics: a brief review. ILAR J (2012) 1.09
LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer (2013) 1.09
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer (2011) 1.05
LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition. Proc Natl Acad Sci U S A (2012) 1.02
Targeting histone lysine demethylases - progress, challenges, and the future. Biochim Biophys Acta (2014) 1.01
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell (2016) 0.98
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer (2014) 0.98
Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair. Nat Commun (2014) 0.98
Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World J Gastroenterol (2012) 0.97
The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep (2013) 0.97
Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. Biochem J (2013) 0.96
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res (2014) 0.96
Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci (2013) 0.96
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Br J Pharmacol (2014) 0.94
Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem (2013) 0.94
Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res Treatment (2012) 0.94
The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia (2013) 0.93
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. Neoplasia (2015) 0.93
Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol (2012) 0.92
Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer (2014) 0.90
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol (2013) 0.89
Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. Oncotarget (2016) 0.89
KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Cell Cycle (2013) 0.88
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep (2014) 0.88
LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16. Mol Cell Biol (2013) 0.87
Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets (2013) 0.87
The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers (Basel) (2011) 0.86
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res (2013) 0.85
Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell (2012) 0.84
KDM1 class flavin-dependent protein lysine demethylases. Biopolymers (2015) 0.84
The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer (2012) 0.84
Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer. Front Oncol (2013) 0.84
KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget (2013) 0.84
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget (2015) 0.83
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget (2015) 0.83
Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer (2014) 0.83
Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci (2016) 0.82
Tipping the lysine methylation balance in disease. Biopolymers (2013) 0.82
Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol (2016) 0.82
PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget (2015) 0.81
Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of β-catenin signaling. Oncogene (2015) 0.81
Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells. PLoS One (2013) 0.81
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats. PLoS One (2013) 0.80
Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer. J Ovarian Res (2015) 0.80
Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures. Bioorg Med Chem (2015) 0.79
NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget (2015) 0.79
Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1. ACS Med Chem Lett (2013) 0.79
3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. Medchemcomm (2014) 0.79
Prognostic role of LSD1 in various cancers: evidence from a meta-analysis. Onco Targets Ther (2015) 0.79
A hypomorphic lsd1 allele results in heart development defects in mice. PLoS One (2013) 0.78
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Ther Adv Hematol (2015) 0.78
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget (2016) 0.78
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent. Oncotarget (2016) 0.77
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget (2016) 0.77
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer. Int J Clin Exp Pathol (2014) 0.77
CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. J Cancer Res Clin Oncol (2014) 0.77
Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity. Neoplasia (2014) 0.77
Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations. Expert Rev Proteomics (2015) 0.77
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells. Oncotarget (2016) 0.77
Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci (2016) 0.77
miR-708/LSD1 axis regulates the proliferation and invasion of breast cancer cells. Cancer Med (2016) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. Sci Rep (2015) 0.76
LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP. Nucleic Acids Res (2016) 0.76
Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population. Am J Cancer Res (2015) 0.76
SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. Oncotarget (2015) 0.76
Histone Demethylases in Colon Cancer. Curr Colorectal Cancer Rep (2014) 0.76
Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells. Oncotarget (2017) 0.75
Compartmentation of metabolites in regulating epigenome of cancer. Mol Med (2016) 0.75
Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells. Med Sci Monit (2016) 0.75
Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Bioorg Med Chem (2016) 0.75
ERRα induces H3K9 demethylation by LSD1 to promote cell invasion. Proc Natl Acad Sci U S A (2017) 0.75
Epigenetic regulation of LSD1 during mammary carcinogenesis. Mol Cell Oncol (2014) 0.75
LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter. Oncotarget (2016) 0.75
The LSD1 Family of Histone Demethylases and the Pumilio Posttranscriptional Repressor Function in a Complex Regulatory Feedback Loop. Mol Cell Biol (2015) 0.75
Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. Sci Rep (2017) 0.75
LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer (2017) 0.75
Magnetofection based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells. Int J Oncol (2016) 0.75
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem (2016) 0.75
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Prepublication data sharing. Nature (2009) 12.24
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet (2008) 9.39
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet (2003) 7.98
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 7.04
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet (2002) 6.46
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet (2004) 6.15
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet (2005) 5.35
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet (2007) 4.99
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci (2004) 4.76
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol (2004) 4.72
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ (2012) 4.64
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet (2003) 4.61
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet (2010) 4.36
A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet (2007) 4.31
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell (2009) 3.94
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol (2008) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer (2004) 3.64
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature (2008) 3.62
Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst (2004) 3.53
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes (2007) 3.24
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet (2005) 3.15
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet (2008) 3.12
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology (2009) 3.04
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet (2005) 3.00
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet (2010) 2.92
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet (2010) 2.81
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun (2003) 2.78
ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet (2007) 2.77
DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene (2004) 2.73
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials (2003) 2.70
Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet (2012) 2.70
Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst (2004) 2.66
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59